 AUSTIN, Texas, Oct. 18, 2021 PRNewswire -- Natera, Inc. NASDAQ: NTRA, a leader in transforming care through genetic and cell-free DNA cfDNA testing, announced the launch and availability of its Prospera donor-derived cfDNA dd-cfDNA transplant assessment test for lung transplant recipients. The launch represents the latest addition to Nateras transplant monitoring portfolio beyond kidney and heart transplantation. 